Dividend compounder review

SYRE

Spyre Therapeutics Inc. · NASDAQ · US

Healthcare · Biotechnology

Chart Factor Intelligence Back to Screener
Score28.00/100
Confidence78.00/100
DecisionInsufficient Data
RatingAvoid
Scoring

Quality breakdown

Dividend Reliability 0.0 / 25 Payment history, cuts, growth, and regularity.
Dividend Sustainability 10.0 / 20 Payout, free cash flow, dividend cover, and debt.
Business Quality 8.0 / 25 Scale, cash generation, growth, margins, and returns.
Valuation Discipline 1.0 / 15 Yield, P/E, and price stretch versus long-term trend.
Long-Term Trend 9.0 / 15 Trend line, long return history, and drawdown control.
Metrics

Dividend and business context

Dividend Years0
Dividend Yield0.00%
Payout Ratio0.0%
Dividend Cut 5YNo
Net Income$-155.2M
Free Cash Flow$-169.3M
FCF Covers DividendUnknown
Debt / Equity0.00
P/E-
Revenue Growth 5Y-62.0%
Net Margin0.0%
ROE-31.1%
Price vs Trend68.8%
3Y Return707.9%
5Y Return-58.7%
CurrencyUSD
Warnings

Review flags

No usable dividend history found.
Free cash flow is negative.
Dividend diary

Activity record

SYRE dividend review warning Warning · Warning

Free cash flow is negative.